Changing Reimbursement Criteria on Anti-VEGF Treatment Patterns Among Wet Age-Related Macular Degeneration and Diabetic Macular Edema Patients: An Interrupted Time Series Analysis.

Background Key Messages Implications for policy makers There was a decreasing trend in the treatment gap between each anti-vascular endothelial growth factor (anti-VEGF) injection for both wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) patients from 2011 to 2019.

also in 47,180 other papers